A-967079 is a potent, selective, and orally bioavailable inhibitor of the TRPA1 channel, developed by developed by Abbott Laboratories for treatment pain disorder. A-967079 potently blocks human and rat TRPA1 channels. A-967079 is 1000-fold selective over other TRP channels and is 150-fold selective over 75 other ion channels, enzymes, and G-protein-coupled receptors. Oral dosing of A-967079 produces robust drug exposure in rodents and exhibits analgesic efficacy in allyl isothiocyanate-induced nocifensive response and osteoarthritic pain in rats. A-967079 attenuates cold allodynia produced by nerve injury but does not alter noxious cold sensation in naive animals, suggesting distinct roles of TRPA1 in physiological and pathological states. Unlike TRPV1 antagonists, A-967079 does not alter body temperature. It also does not produce locomotor or cardiovascular side effects.

A-836339 is a drug that acts as a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptor. It showed analgesic, anti-inflammatory and anti-hyperalgesic effects at low doses. A-836339 was detected in a certain product in Japan and was suggested to be for human consumption.

A-834735 is a drug developed by Abbott Laboratories, acts as a potent cannabinoid receptor full agonist at both the CB1 and CB2 receptors.

A-796260 is a compound that acts as a potent and selective cannabinoid CB2 receptor agonist. The analgesic effects of A-796260 on activity-induced pain behavior were evaluated in a rat model, the results demonstrated that A-796260 may be a useful new pharmacological compound for further studying CB2 receptor pharmacology and for evaluating its role in the modulation of pain.